Reviewing Entera Bio Ltd. (ENTX)’s and Autolus Therapeutics plc (NASDAQ:AUTL)’s results

Both Entera Bio Ltd. (NASDAQ:ENTX) and Autolus Therapeutics plc (NASDAQ:AUTL) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio Ltd. N/A 82.74 10.30M -1.01 0.00
Autolus Therapeutics plc 1.08M 667.26 53.28M -1.40 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Entera Bio Ltd. 0.00% 0% 0%
Autolus Therapeutics plc -4,933.33% 0% 0%

Institutional & Insider Ownership

Institutional investors owned 14.7% of Entera Bio Ltd. shares and 45.07% of Autolus Therapeutics plc shares. About 46.55% of Entera Bio Ltd.’s share are owned by insiders. On the other hand, insiders owned about 3.52% of Autolus Therapeutics plc’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Entera Bio Ltd. -0.47% -4.02% -3.56% -28.27% 0% 32.16%
Autolus Therapeutics plc 2.8% -14.64% -18.32% -50.22% 0% -27.22%

For the past year Entera Bio Ltd. had bullish trend while Autolus Therapeutics plc had bearish trend.


On 5 of the 7 factors Entera Bio Ltd. beats Autolus Therapeutics plc.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.